Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Saredutant

Generic Name: Saredutant

Drug Type: Small Molecule

Chemical Formula: C_₃₁H_₃₅Cl_₂N_₃O_₂

CAS Number: 142001-63-6

Unique Ingredient Identifier: 720U2QK8I5

Overview

Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.

Background

Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.

Indication

Investigated for use/treatment in depression and anxiety disorders.

Associated Conditions

No associated conditions information available.

Clinical Trials

An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder

Phase 3

Completed

Posted: 2008/03/06

Sponsor:Sanofi

ID:NCT00629551

An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder

Phase 3

Completed

Posted: 2007/09/19

Sponsor:Sanofi

ID:NCT00531622

A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression

Phase 3

Completed

Posted: 2007/01/31

Sponsor:Sanofi

ID:NCT00429260

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder

Phase 3

Completed

Posted: 2006/12/29

Sponsor:Sanofi

ID:NCT00417118

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

Phase 3

Completed

Posted: 2006/12/22

Sponsor:Sanofi

ID:NCT00415142

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy